NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy

Active Not RecruitingPhase 1

Sponsor: Eli Lilly and Company

Conditions: Overweight, Obesity

Interventions: LY4167586, Placebo, LY4167586

Countries: United States, Singapore

The purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration. Participation in the study will last approximately 7 months.

Eligibility overview

Sex: ALL

Age: 18 Years to 65 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Participant must be 21 for Singapore site
* Have a body mass index (BMI) between 27.0 kilogram per square meter (kg/m²) and 35.0 kg/m², inclusive
* Have had a self-reported stable weight for 3 months prior to screening (less than approximately 5 percent \[%\] body weight change)

Exclusion Criteria:

* Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study drug, or of interfering with the interpretation of data.
* Is an individual of childbearing potential (IOCBP)

Locations (2)

Madison, Wisconsin, United States
Singapore, Singapore